SureTrader Nadex Advertisement SureTrader
Home > Boards > US OTC > Biotechs >

Galectin Therapeutics Inc. (GALT)

GALT RSS Feed
Add GALT Price Alert      Hide Sticky   Hide Intro
Moderator: Chess Master, GREGG THE GREEK, NeverSettle, sunshinesmiles
Search This Board: 
Last Post: 4/22/2017 11:57:32 AM - Followers: 76 - Board type: Free - Posts Today: 0

Galectin Therapeutics is a biotechnology company focused on discovery and development. We apply our leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on our unique carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function.

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources.

Galectin Therapeutics leverages extensive scientific and development expertise as well as established relationships with outside sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer immunotherapy.
 

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Though we do not have any current marketed products, our research and development programs, designed to ultimately help patients and their physicians, are focused on:

 

Fibrosis

 

Fibrosis is the development of excess fibrous connective tissue in an organ when exposed to a chronic disease. The longer the disease affects the organ, the more fibrous tissue is deposited and this ultimately results in the failure of the organ. Galectin Therapeutics’ drug candidates provide a promising and exciting new approach for the treatment of fibrotic diseases, including liver, lung and kidney fibrosis. Significant unmet need exists for treatment options in fibrosis. For example, there are currently no approved medical treatments available for the millions of patients in the U.S. who have non-alcoholic steatohepatitis with advanced fibrosis – commonly known as fatty liver disease. Learn about fibrosis and our research in this area including galectin effects on liver fibrosis, lung fibrosis and kidney fibrosis.

 

Cancer

 

Cancer harms the body when damaged cells divide uncontrollably to form lumps or masses of tissue called tumors. Research shows the potential for galectin inhibition to play an important role in cancer therapy, particularly tumor immunotherapy – an emerging treatment that enhances the activity of the immune system against cancer cells. There are more than 100 types of cancers, and for many of these cancers, few treatment options exist. Our drug candidates provide a new and complimentary approach to other drugs on the market for the treatment of cancer. Learn more about cancer and immunotherapy.

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GALT
Current Price
Volume:
Bid Ask Day's Range
SureTrader
GALT News: Galectin Therapeutics and Exalenz to Present Late-Breaking Abstract at The International Liver Congress™ 2017 04/18/2017 08:00:00 AM
GALT News: Galectin Therapeutics Reports 2016 Financial Results and Provides Business Update 03/28/2017 08:30:00 AM
GALT News: Current Report Filing (8-k) 03/28/2017 08:22:13 AM
GALT News: Annual Report (10-k) 03/28/2017 08:19:55 AM
GALT News: (25-NSE) 03/23/2017 04:22:16 PM
PostSubject
#3072   BLCM and her University of Michigan CEO Baylor rickyricks 04/22/17 11:57:32 AM
#3071   GALT Clinical Trials: sunshinesmiles 04/21/17 02:03:57 AM
#3070   Bull flag. Nice$ alphaInvestor2 04/20/17 09:52:40 PM
#3069   GALT needs to get on it with testing alphaInvestor2 04/19/17 04:26:14 PM
#3068   still looking strong here Thoro 04/19/17 01:52:31 PM
#3067   I'm surprised BMY hasn't budged on the offer yet. alphaInvestor2 04/18/17 10:03:37 AM
#3066   The 10X fund owns about 21% so it Chess Master 04/18/17 09:27:29 AM
#3065   Institutional buyers on watch. sunshinesmiles 04/17/17 07:13:45 PM
#3064   From the Cerbat Gem Market News on 4/14/17: IRAHopeful 04/17/17 11:16:07 AM
#3063   It is from a subscription service l use, sokol 04/13/17 12:22:34 PM
#3062   Yeah I think we see a little pop NeverSettle 04/13/17 10:24:42 AM
#3061   Looks there are strong support around $3.3, and Maple tree 04/13/17 09:45:33 AM
#3060   Thank you for sharing. Was that from an NeverSettle 04/13/17 08:18:18 AM
#3059   Take this for whatever it is worth, and sokol 04/12/17 10:14:47 PM
#3058   I'd like to hear this as well. Looks NeverSettle 04/12/17 04:01:06 PM
#3057   Can someone elaborate, would that basically mean if gss2003 04/12/17 03:44:28 PM
#3056   Did I understand that GALT received news from IRAHopeful 04/12/17 03:39:01 PM
#3055   Or they will come with offering. They need Coolec78 04/12/17 02:14:25 PM
#3054   Yep, there's no denying that GALT is seriously NeverSettle 04/12/17 07:33:23 AM
#3053   Absolutely except primarily targeting lung fibrosis with inhalers, jmh0602 04/12/17 12:44:58 AM
#3052   i hope you realize that Galecto is a Chess Master 04/11/17 11:51:47 PM
#3051   I think what you want to say is Chess Master 04/11/17 11:50:39 PM
#3050   GALT One year chart shows we are rising sunshinesmiles 04/11/17 11:28:20 PM
#3049   Probably gradually average up Maple tree 04/11/17 11:19:52 PM
#3048   I think people are going to be kicking Chess Master 04/11/17 10:43:24 PM
#3047   We are in the boat and wish to Maple tree 04/11/17 06:33:13 PM
#3046   If you don't mind, I'd like to go NeverSettle 04/11/17 05:25:48 PM
#3045   Nov 2, 2014 the option agreement was announced jmh0602 04/11/17 05:20:19 PM
#3044   Uh, that article was written 30 days ago :) NeverSettle 04/11/17 05:16:07 PM
#3043   Uh, that was another company and was announced jmh0602 04/11/17 05:14:57 PM
#3040   I've watched this since before $2. I Thoro 04/11/17 02:28:43 PM
#3039   GALT looks wound up tight. I expect to NeverSettle 04/11/17 01:01:25 PM
#3038   Agree, Galt could go back all time high Maple tree 04/11/17 07:11:44 AM
#3037   Did I mention I like GALT? sunshinesmiles 04/10/17 11:26:04 PM
#3036   GALT has an Institutional buyer named Blackrock. sunshinesmiles 04/10/17 11:21:04 PM
#3035   GALT is worthy to be watched. sunshinesmiles 04/10/17 11:17:12 PM
#3034   Checking out GALT since $2. sunshinesmiles 04/10/17 11:16:33 PM
#3033   This is interesting https://www.google.com/amp/s/www.thestreet.com/amp/story/13 Coolec78 04/10/17 02:27:57 PM
#3032   You did a better job of explaining than GREGG THE GREEK 04/10/17 12:34:24 PM
#3031   Thanks. Watch this from under $2 and just Maple tree 04/10/17 12:26:43 PM
#3030   Thanks Maple tree 04/10/17 12:25:11 PM
#3029   Whats driving it right now is a realization Chess Master 04/10/17 12:07:31 PM
#3028   This is the rison, I think... http://labiotech.eu/galecto-biotech-bms-td139-phas Coolec78 04/10/17 11:49:06 AM
#3027   What drives this up? Could you explain? Maple tree 04/10/17 11:40:12 AM
#3026   Definitely not I hub money moving GALT GREGG THE GREEK 04/10/17 11:34:21 AM
#3025   they need the skin partnership to protect the gss2003 04/09/17 12:33:30 PM
#3023   I agree that he has the right to RyGuy 04/08/17 11:11:30 PM
#3022   The fact that he talked so specifically about Chess Master 04/08/17 10:16:20 PM
#3021   Don't you think Traber is so sure of Coolec78 04/08/17 10:00:41 PM
#3020   Very well stated. Agree with the price Chess Master 04/08/17 09:49:52 PM
PostSubject